Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7676356 | 0.91 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL7210642 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7682625 | 0.91 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL6710559 | 0.90 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL7680836 | 0.90 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL7676523 | 0.89 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL7215484 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7210588 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5313386 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3824218 | 0.80 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| US-6395724-B1 | COMPLEXES; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETICS | ADVANCED MEDICINE, INC. | 2002-05-28 | — | — | US | disclosed |
| WO-1999063939-A9 | MULTIBINDING INHIBITORS OF CYCLOOXYGENASE-2 | ADVANCED MEDICINE INC (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-1085845-A2 | MULTIBINDING INHIBITORS OF CYCLOOXYGENASE-2 | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063939-A2 | MULTIBINDING INHIBITORS OF CYCLOOXYGENASE-2 | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | PTGS2 2939/4885PTGS1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.